Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04476537 · ClinicalTrials.gov registry record · NA

RNA Precision Oncology in Advanced Pancreatic Cancer

A NA study, sponsored by Columbia University.

Terminated
Registry status
NA
Development phase
16
Enrollment target

NCT04476537 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04476537, a NA study, was terminated before completion, sponsored by Columbia University.

TERMINATED
Registry status
NA
Development phase
16 participants
Enrollment target

Study Summary

The overall objective of this project is to determinate the feasibility of administering personalized therapy to subjects with advanced pancreatic cancer utilizing the novel OncoTreat platform. The primary objective of this study is to assess the feasibility of implementing the OncoTreat framework in patients with newly diagnosed, untreated metastatic pancreatic adenocarcinoma.

Interventions

  • DEVICE OncoTreat

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2020-12-07
Est. Completion 2023-03-31
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT04476537

The ClinicalTrials.gov registry entry for NCT04476537 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which OncoTreat is the first listed.

NCT04476537 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04476537 about?

NCT04476537 is a clinical study titled "RNA Precision Oncology in Advanced Pancreatic Cancer". The overall objective of this project is to determinate the feasibility of administering personalized therapy to subjects with advanced pancreatic cancer utilizing the novel OncoTreat platform. The primary objective of this study is to assess the feasibility of implementing the OncoTreat framework i...

What is the current status of trial NCT04476537?

This trial is currently terminated. It is a NA study. The enrollment target is 16 participants. The study started on 2020-12-07. Estimated completion is 2023-03-31.

What interventions are being tested in trial NCT04476537?

The interventions under investigation include: OncoTreat (DEVICE).

Who is sponsoring clinical trial NCT04476537?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.